Key Metrics Reveal Insights on Rayonier Advanced Materials (RYAM) Q3 Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Source: NASDAQ.COM
Quarterly Performance: Rayonier Advanced Materials (RYAM) reported a revenue of $353 million for Q3 2025, a 12% decline from the previous year, with an EPS of -$0.07, slightly improved from -$0.12 a year ago.
Earnings Surprise: The revenue fell short of the Zacks Consensus Estimate of $376.4 million by 6.22%, and the EPS matched the consensus estimate, indicating no surprise in earnings.
Investor Insights: Investors are closely monitoring year-over-year revenue and earnings changes, as well as comparisons to Wall Street expectations, to gauge the company's financial health and stock performance.
Additional Resources: Zacks Investment Research offers insights and recommendations, including a report on the "7 Best Stocks for the Next 30 Days."
Get Free Real-Time Notifications for Any Stock
Monitor tickers like RYAM with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on RYAM
Wall Street analysts forecast RYAM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RYAM is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 8.530
Low
9.00
Averages
9.00
High
9.00
Current: 8.530
Low
9.00
Averages
9.00
High
9.00
About RYAM
Rayonier Advanced Materials Inc. specializes in cellulose-based technologies, including cellulose specialties, a natural polymer commonly used in the production of filters, food, pharmaceuticals and other industrial applications. The Company's segments include Cellulose Specialties, Cellulose Commodities, Biomaterials, Paperboard and High-Yield Pulp. The Company's specialized assets, capable of creating cellulose specialties products, are also used to produce commodity fluff pulp, biofuels, bioelectricity and other biomaterials such as bioethanol and tall oils. Its commodity fluff is typically used in consumer products such as baby diapers. Its tall oil soap is used as feedstock for producing crude tall oil. It manufactures products for the paper and packaging markets. It is a multi-ply paperboard producer in North America. It produces its high-yield pulp primarily from hardwood aspen, maple and birch species. It has manufacturing operations in the United States, Canada and France.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Material Stocks Receive 'F' EPS Revision Grades, Indicating Weak Earnings Momentum
- EPS Revision Grade Analysis: As the earnings season approaches, an analysis reveals that several mid to low cap material stocks have received an 'F' EPS revision grade, indicating significant downward pressure on future earnings expectations, which may lead to decreased investor confidence.
- List of Affected Companies: Companies such as American Battery Technology Company (ABAT), Algoma Steel Group Inc. (ASTL), and Eastman Chemical Company (EMN) have all received an 'F' grade, highlighting serious challenges in their earnings momentum.
- Market Impact Assessment: The poor EPS revision grades of these companies could adversely affect their stock performance, prompting investors to carefully assess associated risks, especially during the earnings season when market sensitivity to earnings is heightened.
- Industry Outlook: With the earnings season underway, the overall performance of the materials sector may be dragged down by these low-rated companies, leading investors to seek out better-performing firms within the industry for potential investment opportunities.
Continue Reading
Altimmune Inc Receives FDA Breakthrough Therapy Designation for Pemvidutide, Shares Surge 23.6%
- FDA Certification Impact: Altimmune Inc's Pemvidutide received FDA Breakthrough Therapy Designation, leading to a 23.6% surge in shares to $4.34 on Monday, indicating strong market confidence in its potential efficacy and possibly accelerating its path to market.
- Clinical Progress: GH Research PLC's GH001 lifted from FDA clinical hold saw shares rise 33.8% to $17.72, reflecting significant advancements in drug development that are expected to enhance its competitive position in the market.
- Executive Change: Rayonier Advanced Materials Inc appointed Scott M. Sutton as the new CEO, resulting in a 14.1% increase in shares to $6.68, suggesting that this leadership change could bring new strategic directions and growth opportunities for the company.
- Market Rebound: The overall market showed strong performance with the S&P 500 index rising, reflecting investor optimism about economic recovery, which may drive more capital inflows into the stock market.
Continue Reading